Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
about
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@ast
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@en
type
label
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@ast
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@en
prefLabel
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@ast
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@en
P2093
P2860
P1476
Phase II study of mFOLFOX3 (5- ...... tastatic biliary tract cancer.
@en
P2093
Eun Mi Nam
Hyo Rak Lee
Hyun Jung Jun
In Gyu Hwang
Joon Oh Park
Joung-Soon Jang
Kyong-Choun Chi
Myung Hwan Rho
Sung Yong Oh
P2860
P2888
P304
P356
10.1007/S00280-015-2691-1
P577
2015-02-13T00:00:00Z
P6179
1035449356